DRUG ALERT: Emerade solution for injection pre-filled syringe 300mcg

07 Apr 2020

(Manufactured by Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited)) PL 33616/0014

A Class 2 medicines recall for Emerade solution for injection pre-filled syringe 300mcg – Action within 48 hours (Ref: EL(20)A/20) (7 April 2020) has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA). Please note that this is a recall for Emerade 300mcg pens only. This is a different alert to that issued on 4 March 2020 for Emerade 150 microgram auto-injectors.

The recall is for all batches of unexpired stock of Emerade solution for injection pre-filled syringe 300mcg due to an error in one of the auto-injector components causing some auto-injectors to fail to trigger and deliver an adrenaline dose.

The alert issued today for Emerade 300mcg pens contains important information in relation to Coronavirus (COVID-19) to support you in managing the supply of alternative adrenaline auto-injectors (AAIs) to patients while adhering to the current Government advice on social distancing, isolation and shielding. Please read the information carefully so that you can manage this recall safely. Full details are available here.

 

Patient safety in using alternative AAIs

Patients/carers should, where possible, be trained in the correct use of the new AAIs prescribed as an alternative. This is very important so that they can use their new AAI device correctly.

·         Training materials for the different AAI are available here.

·         Additionally, information about how to use the various AAI devices is available in the Summary of Product Characteristics (SPC) of the relevant product, as well as in the Patient Information Leaflet (PIL), accessible via the electronic medicines compendium (emc) website.

·         You may wish to obtain training pens from manufacturers to assist you in training patients/carers in the use of their new pens; these should be available free of charge from manufacturers.

MHRA letters for patients and carers to help explain the drug alert and alternatives plus actions to take are available here.

Please contact the Pharmacy Services Team for further information if required on 01727891800, or email us at pharmacyservices@npa.co.uk.